<DOC>
	<DOCNO>NCT00998101</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin ixabepilone , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block cancer growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry cancer-killing substance . Giving chemotherapy together monoclonal antibody may better way block cancer growth . PURPOSE : This phase II trial study side effect well give carboplatin ixabepilone together cetuximab work treat patient stage III stage IV non-small cell lung cancer previously untreated chemotherapy .</brief_summary>
	<brief_title>Carboplatin , Ixabepilone , Cetuximab Patients With Stage III Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate disease-control rate patient advance chemotherapy-naive non-small cell lung cancer 2 course carboplatin , ixabepilone , cetuximab . Secondary - To estimate progression-free survival patient treat regimen . - To estimate overall survival patient treat regimen . - To estimate toxicity regimen patient . - To determine potential predictive marker efficacy ixabepilone cetuximab . ( exploratory ) - To investigate prevalence cetuximab IgE antibody , rate cetuximab hypersensitivity reaction patient without evidence cetuximab IgE antibody . OUTLINE : This multicenter study . Patients receive carboplatin IV 30 minute ixabepilone IV 3 hour day 1 cetuximab IV 1-2 hour day 1 , 8 15 . Treatment repeat every 21 day 2-4 course absence disease progression unacceptable toxicity . Treatment modification may apply accord response . Tumor tissue blood sample collect analysis . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Chemotherapynaive Stage IIIB disease amenable surgery pleural effusion , pericardial effusion , candidate chemoradiotherapy Stage IV disease Must pathology block unstained slide initial subsequent diagnosis Diagnosis make via core biopsy ( fineneedle aspirate ) require Measurable disease define RECIST guideline For patient receive prior radiotherapy , evaluable disease must outside radiation field , new lesion develop within radiation field Brain metastasis allow provide treat determine controlled treat physician No IgE cetuximab antibody PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Creatinine &lt; 2.0 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN presence hepatic metastasis ) Bilirubin ≤ 1.5 time ULN Prior malignancy allow provided treating physician determine patient 's life expectancy best define diagnosis nonsmall cell lung cancer ( NSCLC ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No peripheral neuropathy ≥ grade 2 NCI CTCAE v. 3.0 No prior severe allergic reaction follow : Carboplatin Taxane therapy Monoclonal antibody Hypersensitivity ( NCI CTCAE grade34 ) drug formulate Cremophor® EL ( polyoxyethylated castor oil ) No active uncontrolled infection No significant history uncontrolled cardiac disease include , limited , follow : Uncontrolled hypertension Unstable angina Myocardial infarction within past 6 month Uncontrolled congestive heart failure Cardiomyopathy decrease ejection fraction No underlie interstitial lung disease PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 1 week since prior concurrent therapeutic radiotherapy Palliative radiotherapy painful bone lesion allow At least 6 month since prior adjuvant chemotherapy No investigational agent ( ) within past 30 day Not require concurrent treatment follow : Ketoconazole Itraconazole Ritonavir Amprenavir Indinavir Nelfinavir Delavirdine Voriconazole No concurrent chemotherapy cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>